Victoria Johnson

Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.

More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.

The data also support the validity of further research into targeting CD-40 signaling in patients with RA not responding to treatment.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.

Received care was highly variable among ethnicities and gender and often contradicted current guidelines.

In other populations, JAKis demonstrated at least a similar pain benefit to b/tsDMARDs from baseline.

To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.

Calabrese discussed factors for rheumatologists to keep in mind, including recent travel and screening for viral infections.

Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.

Younger people and people without European origin were less likely to adhere to urate-lowering therapy.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

Further data will be presented at the 2024 AANEM Meeting in Georgia in October.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

Calabrese discussed the multi-faceted role of viral infections in the field of rheumatology ahead of the 2024 CCR West meeting.

BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.

Gender, age, and disease duration significantly affected symptom variations.

Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.

The model gave special emphasis to words noting pain, fatigue and depressed moods.

The increase will largely be driven by population growth and aging.

Digital ACT demonstrated superiority over active control in a number of outcomes in a phase 3 trial.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

Types of occupation did not significantly affect response to treatment.